Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with chronic mitral valve disease

Jung Kook Kim, Jun Seok Park, Kyoung Won Seo, Kun Ho Song

Research output: Contribution to journalArticle

Abstract

Recently assessment of suppression of tumorigenicity 2 (ST2) level has become a useful cardiac biomarker in human medicine. This study compared serum ST2 levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels between healthy dogs and dogs with chronic mitral valve disease. Twenty client-owned dogs were investigated. Dogs were divided into normal, asymptomatic, and symptomatic groups. Serum samples were used to measure levels of NT-proBNP and ST2. Samples for NT-proBNP were sent to IDEXX laboratory for analysis while ST2 levels were measured by using a canine interleukin 33 receptor ELISA kit. There was a significant difference in NT-proBNP levels between asymptomatic and symptomatic groups (P < 0.01), and between normal and symptomatic groups (P < 0.01). In contrast, ST2 levels were not relatively different between asymptomatic and symptomatic groups (P > 0.05). There was no significant difference was observed among all groups in ST2 study. The usefulness of measuring NT-proBNP level as a cardiac biomarker in dogs with chronic mitral valve disease was confirmed, but usefulness of the ST2 level was not observed. Further investigations are needed to evaluate the potential usefulness of ST2 level as a cardiac biomarker in canines.

Original languageEnglish (US)
Pages (from-to)35-38
Number of pages4
JournalJournal of Veterinary Clinics
Volume35
Issue number2
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Fingerprint

natriuretic peptides
Brain Natriuretic Peptide
Mitral Valve
biomarkers
Biomarkers
Dogs
dogs
Canidae
Serum
interleukins
Enzyme-Linked Immunosorbent Assay
Medicine
heart valve diseases
medicine
enzyme-linked immunosorbent assay
sampling
receptors

Keywords

  • Cardiac biomarker
  • CMVD
  • Level
  • NT-proBNP
  • ST2

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with chronic mitral valve disease. / Kim, Jung Kook; Park, Jun Seok; Seo, Kyoung Won; Song, Kun Ho.

In: Journal of Veterinary Clinics, Vol. 35, No. 2, 01.04.2018, p. 35-38.

Research output: Contribution to journalArticle

@article{1a7d8422e2b644d894e81026ce9aff3d,
title = "Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with chronic mitral valve disease",
abstract = "Recently assessment of suppression of tumorigenicity 2 (ST2) level has become a useful cardiac biomarker in human medicine. This study compared serum ST2 levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels between healthy dogs and dogs with chronic mitral valve disease. Twenty client-owned dogs were investigated. Dogs were divided into normal, asymptomatic, and symptomatic groups. Serum samples were used to measure levels of NT-proBNP and ST2. Samples for NT-proBNP were sent to IDEXX laboratory for analysis while ST2 levels were measured by using a canine interleukin 33 receptor ELISA kit. There was a significant difference in NT-proBNP levels between asymptomatic and symptomatic groups (P < 0.01), and between normal and symptomatic groups (P < 0.01). In contrast, ST2 levels were not relatively different between asymptomatic and symptomatic groups (P > 0.05). There was no significant difference was observed among all groups in ST2 study. The usefulness of measuring NT-proBNP level as a cardiac biomarker in dogs with chronic mitral valve disease was confirmed, but usefulness of the ST2 level was not observed. Further investigations are needed to evaluate the potential usefulness of ST2 level as a cardiac biomarker in canines.",
keywords = "Cardiac biomarker, CMVD, Level, NT-proBNP, ST2",
author = "Kim, {Jung Kook} and Park, {Jun Seok} and Seo, {Kyoung Won} and Song, {Kun Ho}",
year = "2018",
month = "4",
day = "1",
doi = "10.17555/jvc.2018.04.35.2.35",
language = "English (US)",
volume = "35",
pages = "35--38",
journal = "Journal of Veterinary Clinics",
issn = "1598-298X",
publisher = "Korean Society of Veterinary Clinics",
number = "2",

}

TY - JOUR

T1 - Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with chronic mitral valve disease

AU - Kim, Jung Kook

AU - Park, Jun Seok

AU - Seo, Kyoung Won

AU - Song, Kun Ho

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Recently assessment of suppression of tumorigenicity 2 (ST2) level has become a useful cardiac biomarker in human medicine. This study compared serum ST2 levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels between healthy dogs and dogs with chronic mitral valve disease. Twenty client-owned dogs were investigated. Dogs were divided into normal, asymptomatic, and symptomatic groups. Serum samples were used to measure levels of NT-proBNP and ST2. Samples for NT-proBNP were sent to IDEXX laboratory for analysis while ST2 levels were measured by using a canine interleukin 33 receptor ELISA kit. There was a significant difference in NT-proBNP levels between asymptomatic and symptomatic groups (P < 0.01), and between normal and symptomatic groups (P < 0.01). In contrast, ST2 levels were not relatively different between asymptomatic and symptomatic groups (P > 0.05). There was no significant difference was observed among all groups in ST2 study. The usefulness of measuring NT-proBNP level as a cardiac biomarker in dogs with chronic mitral valve disease was confirmed, but usefulness of the ST2 level was not observed. Further investigations are needed to evaluate the potential usefulness of ST2 level as a cardiac biomarker in canines.

AB - Recently assessment of suppression of tumorigenicity 2 (ST2) level has become a useful cardiac biomarker in human medicine. This study compared serum ST2 levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels between healthy dogs and dogs with chronic mitral valve disease. Twenty client-owned dogs were investigated. Dogs were divided into normal, asymptomatic, and symptomatic groups. Serum samples were used to measure levels of NT-proBNP and ST2. Samples for NT-proBNP were sent to IDEXX laboratory for analysis while ST2 levels were measured by using a canine interleukin 33 receptor ELISA kit. There was a significant difference in NT-proBNP levels between asymptomatic and symptomatic groups (P < 0.01), and between normal and symptomatic groups (P < 0.01). In contrast, ST2 levels were not relatively different between asymptomatic and symptomatic groups (P > 0.05). There was no significant difference was observed among all groups in ST2 study. The usefulness of measuring NT-proBNP level as a cardiac biomarker in dogs with chronic mitral valve disease was confirmed, but usefulness of the ST2 level was not observed. Further investigations are needed to evaluate the potential usefulness of ST2 level as a cardiac biomarker in canines.

KW - Cardiac biomarker

KW - CMVD

KW - Level

KW - NT-proBNP

KW - ST2

UR - http://www.scopus.com/inward/record.url?scp=85052234242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052234242&partnerID=8YFLogxK

U2 - 10.17555/jvc.2018.04.35.2.35

DO - 10.17555/jvc.2018.04.35.2.35

M3 - Article

AN - SCOPUS:85052234242

VL - 35

SP - 35

EP - 38

JO - Journal of Veterinary Clinics

JF - Journal of Veterinary Clinics

SN - 1598-298X

IS - 2

ER -